Soft Tissue Sarcoma
Soft tissue sarcomas are rare and histologically diverse tumors arising from muscle, fat, nerves, and connective tissue, where expert sarcoma pathology review is essential to avoid misclassification. Driver alterations including MDM2 amplification in liposarcoma, SS18-SSX in synovial sarcoma, and NTRK fusions define subtype-specific therapeutic targets. CancerFax connects patients with specialist sarcoma centers and subtype-specific clinical trials.
- Histologic subtype, MDM2 & fusion oncogene profiling
- Trabectedin, TRK inhibitors & CDK4-targeted access
- Specialist sarcoma center & subtype-specific trial access
- Incidence
- ~1% of all adult malignancies; 50+ recognized subtypes
- Most Common Sites
- Extremities (~50%), Retroperitoneum (~15%), Trunk wall
- Key Diagnostic Test
- Core needle biopsy + immunohistochemistry + molecular/NGS panel
- Grading System
- FNCLCC Grade 1–3 (differentiation + necrosis + mitosis)
- Advanced Therapies
- Trabectedin, Pazopanib, Imatinib (GIST), Larotrectinib, TIL Trials
What is Soft Tissue Sarcoma
Types and Subtypes of Soft Tissue Sarcoma
Soft tissue sarcomas can be categorized on the basis of lineages, or more specifically, on the basis of their resemblance to the tissue types they come from. The following are some important categories of soft tissue sarcomas. These are also characterized molecularly, which in many instances is diagnostic in nature.
Symptoms and Signs of Soft Tissue Sarcoma
Many times, soft tissue sarcomas have an insidious onset, with a painless lesion or mass which is usually considered to be either lipomatous, a hematoma, or even just a muscle strain until it becomes too large to ignore. This delay in diagnosis due to its lack of early symptoms accounts for the many cases of soft tissue sarcomas being discovered when they are already locally advanced or metastatic.
Causes and Risk Factors
The majority of soft tissue sarcomas arise sporadically with no identifiable predisposing cause. However, several genetic predispositions, environmental exposures, and iatrogenic factors are established risk factors and are important for clinical risk stratification, genetic counseling, and surveillance in affected families.
Diagnosis and Investigations
STS can be diagnosed through the use of tissue, more particularly, a core needle biopsy done via an image-guided procedure either through ultrasound or CT scan using a defined approach that would avoid contaminating future surgery fields. This biopsy sample should then undergo evaluation by a pathologist who specializes in sarcomas. Panels of immunohistochemistry (IHC), as well as molecular tests such as FISH, RT-PCR, or NGS, will be needed to sub-type the diagnosis.
Staging and Risk Stratification
Staging of soft tissue sarcomas is done using the AJCC TNM staging system, based on tumor size (T), involvement of regional lymph nodes (N), distant metastasis (M), and histologic grade (G – obtained from FNCLCC grading). Histologic grade is incorporated in the staging process and is arguably one of the most critical factors when it comes to predicting metastatic risk, together with tumor size.
Standard Treatment Options
Treatment of STS is highly dependent on subtype and needs to be performed by a multispecialty team specializing in sarcoma care. For localized disease, surgery is considered the mainstay of treatment, whereas for systemic disease, treatment is determined based on subtype, grade, and molecular characteristics. The general principles of treatment listed below hold true for conventional STS in general.
Advanced and Emerging Therapies
The field of STS treatments has seen tremendous expansion with the availability of targeted drugs for certain molecular subtypes, angiogenesis inhibitors that have a wider range of effects, and novel therapies based on immunology. This treatment process is extremely subtype-dependent because what may work for one type of STS is not relevant to another.
Targeted Therapy
Imatinib (GIST — KIT/PDGFRA Mutant)
The paradigm-setting targeted therapy for GIST. Imatinib is first-line for KIT-mutant and PDGFRA non-D842V-mutant GIST, with response rates exceeding 80%. Adjuvant imatinib is standard for high-risk resected GIST (3 years). CancerFax supports patients in accessing imatinib and monitoring mutations driving resistance.
Targeted Therapy
Avapritinib (PDGFRA D842V-Mutant GIST)
Specifically approved for GIST harboring PDGFRA exon 18 D842V mutations — a population that is imatinib-resistant. Avapritinib achieves high response rates in this subgroup. Mutation testing at diagnosis is mandatory to identify eligible patients.
Targeted Therapy
Larotrectinib / Entrectinib (NTRK Fusion-Positive STS)
NTRK inhibitors are approved in a tumor-agnostic context for NTRK fusion-positive tumors, including infantile fibrosarcoma (ETV6-NTRK3) and other rare NTRK-fusion STS. Response rates are high and durable. CancerFax assists in identifying fusion-positive patients and accessing NTRK inhibitors globally.
Chemotherapy
Trabectedin (Liposarcoma and Leiomyosarcoma)
A marine-derived alkylating agent with particular activity in myxoid/round cell liposarcoma (through interaction with FUS-DDIT3 fusion protein) and leiomyosarcoma. Approved as second-line therapy for advanced LPS and LMS in the EU, US, and many other jurisdictions. Available at specialist oncology centers.
Targeted Therapy
Pazopanib (Non-Adipocytic, Non-GIST STS)
A multitargeted anti-angiogenic TKI approved for pre-treated, non-adipocytic soft tissue sarcoma (excluding GIST and liposarcoma). Provides disease control and prolonged progression-free survival in eligible patients. Active in synovial sarcoma, LMS, and other subtypes.
Targeted Therapy
Selinexor (Dedifferentiated Liposarcoma)
A selective inhibitor of nuclear export (SINE) that targets XPO1/CRM1, approved for dedifferentiated liposarcoma in some markets after failure of prior systemic therapy. Represents a mechanistically novel option for a subtype with limited treatment options beyond first-line doxorubicin.
Immunotherapy
Checkpoint Inhibitors (Alveolar Soft Part Sarcoma, TMB-High STS)
Anti-PD-1/PD-L1 immunotherapy has demonstrated particularly notable activity in alveolar soft part sarcoma (atezolizumab, pembrolizumab) and is being evaluated in other STS subtypes including angiosarcoma and undifferentiated sarcoma. For TMB-high or dMMR STS, pembrolizumab has tumor-agnostic approval. Immunotherapy for broad STS populations remains under investigation.
Targeted Therapy
MEK Inhibitors (NF1-Associated MPNST)
NF1-associated MPNST harbors constitutive RAS-MAPK pathway activation. MEK inhibitors including binimetinib and selumetinib are under investigation in MPNST, with selumetinib having demonstrated activity in NF1-associated plexiform neurofibromas and MPNST in clinical trials.
Cellular Therapy
Adoptive T-Cell Therapy (NY-ESO-1 TCR, TIL — Synovial Sarcoma)
Synovial sarcoma highly expresses the cancer-testis antigen NY-ESO-1. NY-ESO-1-specific T-cell receptor (TCR) engineered T-cell therapy has shown responses in relapsed synovial sarcoma in clinical trials. TIL therapy for other STS subtypes is under early investigation. These approaches are available at specialist academic sarcoma centers.
Biomarkers and Precision Medicine in Soft Tissue Sarcoma
The role of biomarkers for STS includes both diagnosis and prognosis, where diagnosis helps in determining the exact type of STS and prognosis assists in determining the right systemic treatment. Biomarker types differ based on the subtypes, which means there are more than 50 types, and different biomarkers work well with different subtypes.
When to Seek a Second Opinion
STS diagnostics, pathology, and treatment planning are some of the most challenging aspects in oncology. Several studies have shown that there is a significant percentage of patients whose diagnosis, grade, or treatment plan will change once their case is referred to a specialist institution for review. The second opinion is not only advised but expected in any good STS program.
Clinical Trials and Research in Soft Tissue Sarcoma
Prognosis and Key Outcome Factors
The prognosis of soft tissue sarcomas is extremely variable depending on many factors such as the grade of a tumor, its size, how far the tumor infiltrates the tissues, the presence or absence of involvement of any lymph nodes, the metastatic process, and, perhaps, most importantly, its histological type. Given that different types of soft tissue sarcomas vary greatly and could be slow-growing tumors on one hand and very malignant ones prone to early dissemination even before the start of therapy on the other hand, each case requires an individual approach and prognosis taking all this into consideration.
Supportive Care and Living With Soft Tissue Sarcoma
Treatment of soft tissue sarcomas, especially surgical intervention and radiotherapy, has important functional considerations, which are dependent upon the location of the sarcoma and the degree of treatment. Adequate support and rehabilitation therapy in order to improve psychosocial and physical wellbeing is essential for quality of life post-treatment.
How CancerFax Helps You Explore Treatment Options
CancerFax supports patients with soft tissue sarcoma in accessing specialist sarcoma pathology review and subtype confirmation, second opinions on surgical planning and systemic therapy selection, targeted therapy eligibility assessment based on molecular profiling, and identification of clinical trial opportunities — including at sarcoma centers in China and internationally.
Get a free case reviewFrequently Asked Questions About Soft Tissue Sarcoma
Soft tissue sarcoma (STS) is a malignant tumor arising from mesenchymal tissue — the cells that give rise to muscle, fat, blood vessels, nerves, tendons, and connective tissue throughout the body. More than 50 histologically distinct subtypes are recognized, making it one of the most heterogeneous cancer groups. STS accounts for approximately 1% of all adult cancers and a higher proportion of pediatric cancers. The rarity of STS means that most patients should seek care at or in consultation with a specialist sarcoma center, where the full range of diagnostic and treatment expertise is available.
The most commonly diagnosed STS subtypes in adults include undifferentiated pleomorphic sarcoma (UPS), liposarcoma (several subtypes), leiomyosarcoma, synovial sarcoma, and gastrointestinal stromal tumor (GIST). In children and adolescents, rhabdomyosarcoma and Ewing sarcoma are the most common types. Each subtype has distinct biology, preferred anatomic location, molecular drivers, and treatment pathway. The subtype — not just the diagnosis of 'sarcoma' — determines which drugs are appropriate and what the prognosis is likely to be.
The biopsy tract in STS must be planned by the surgeon who will perform the definitive resection, because the tract will be excised en bloc with the tumor at surgery. An improperly placed biopsy can contaminate tissue planes, making subsequent limb-sparing surgery impossible and potentially necessitating amputation that would otherwise have been avoidable. Additionally, interpreting the biopsy requires specialist sarcoma pathology expertise — misclassification of STS subtype occurs in up to 30–40% of cases reviewed outside expert centers, with direct consequences for treatment selection.
STS is graded using the FNCLCC (French) system, which scores three parameters — tumor differentiation, mitotic count, and extent of tumor necrosis — to produce a grade of 1 (low), 2 (intermediate), or 3 (high). Grade is one of the most important prognostic and treatment-guiding variables. Low-grade STS (Grade 1) has limited metastatic potential and is often managed with surgery alone. High-grade STS (Grade 3) carries a substantially higher risk of distant metastasis and is the disease stage for which systemic chemotherapy is most strongly considered.
Chemotherapy is used for specific STS situations: neoadjuvant or adjuvant treatment of high-grade, large Stage III tumors; first-line treatment of metastatic STS (doxorubicin ± ifosfamide); and as a central component of multimodal treatment in certain subtypes (rhabdomyosarcoma, Ewing sarcoma, synovial sarcoma). However, many STS subtypes — including low-grade liposarcoma and most GIST cases — are not treated with conventional chemotherapy. Subtype-specific regimens and targeted therapies have replaced broad-spectrum chemotherapy in a growing proportion of patients with molecularly defined STS.
Several approved targeted therapies are available for specific STS subtypes. Imatinib, sunitinib, regorafenib, and ripretinib are used sequentially for GIST based on KIT/PDGFRA mutation status; avapritinib is specifically approved for PDGFRA D842V-mutant GIST. Larotrectinib and entrectinib are approved for NTRK fusion-positive STS (including infantile fibrosarcoma). Trabectedin is approved for liposarcoma and leiomyosarcoma. Pazopanib is approved for non-adipocytic, non-GIST STS. Additional targeted agents including MDM2 inhibitors and MEK inhibitors are being evaluated in clinical trials for specific molecular subgroups.
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the GI tract, driven in most cases by mutations in the KIT or PDGFRA gene. Unlike most other STS subtypes, GIST is not treated with standard doxorubicin-based chemotherapy — it is relatively resistant to conventional cytotoxics but highly sensitive to imatinib and other tyrosine kinase inhibitors targeting mutant KIT or PDGFRA. Treatment decisions are driven by mutation testing results. CancerFax can assist GIST patients with mutation-specific therapy selection, access to newer TKIs, and clinical trial identification.
Molecular testing in STS serves two critical purposes. First, in many subtypes it is required for diagnosis — a specific fusion (SS18-SSX for synovial sarcoma, FUS-DDIT3 for myxoid liposarcoma, ASPSCR1-TFE3 for ASPS) or amplification (MDM2/CDK4 for liposarcoma) is pathognomonic. Second, it identifies actionable targets for targeted therapy (KIT/PDGFRA for GIST, NTRK fusions for larotrectinib eligibility, NF1 for MEK inhibitor trials) and immunotherapy eligibility (PD-L1, TMB, MSI). Comprehensive NGS-based molecular profiling is recommended for all advanced, recurrent, or metastatic STS.
Limb-sparing (limb-salvage) surgery is achievable in over 90% of extremity STS cases when performed at specialist sarcoma centers with appropriate surgical expertise, imaging, and neoadjuvant therapy resources. Amputation may be required in a minority of cases where the tumor extensively involves the neurovascular bundle of the limb without feasible reconstruction, where prior radiation has compromised tissue, or where the functional outcome after limb-sparing surgery would be inferior to prosthetic function. Before accepting a recommendation for amputation, patients should obtain a second opinion from a specialist sarcoma surgical center.
Yes. CancerFax supports patients with soft tissue sarcoma across all stages of the treatment journey. Our services include specialist sarcoma pathology review coordination, second opinions on subtype classification and surgical planning, molecular profiling interpretation, and identification of subtype-specific targeted therapy and clinical trial opportunities. For patients with GIST, NTRK-fusion sarcoma, synovial sarcoma, or other molecularly defined subtypes, CancerFax helps access the most current approved and investigational therapies — including options at specialist sarcoma centers in China and internationally. We also support patients navigating decisions about neoadjuvant therapy, limb preservation, and metastatic disease management. Send your medical reports to our team to begin the process.